Larotrectinib sulfate是一种口服、ATP竞争性的高选择性TRK抑制剂,对TRKA、B、C三个亚型均具有纳摩尔级别的抑制活性。
|
英文别名 (English Synonym) |
Larotrectinib sulfate |
|
中文名称 (Chinese Name) |
|
|
靶点 (Target) |
Trk |
|
通路 (Pathway) |
Protein Tyrosine Kinase |
|
CAS号 (CAS NO.) |
1223405-08-0 |
|
分子式 (Formula) |
C21H24F2N6O6S |
|
分子量 (Molecular Weight) |
526.51 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Kathryn G, et al. Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood 2016 128:278.[2]Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct,5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27. PMID: 26216294, PMCID: PMC4635026.
